**Core tip:** Endoscopic biliary stenting for benign biliary strictures (BBS) is useful for symptom relief and less invasive than surgery. Therefore, BBS caused by chronic pancreatitis (CP) is often managed by biliary stenting. However, subsequent treatment for refractory BBS caused by CP is unclear and no predictive factors for therapeutic success have been defined. The results of the present study indicated that endoscopic therapy with multiple biliary stenting was effective against the refractory BBS caused by chronic calcifying pancreatitis. Moreover, our study indicated that stricture length was correlated with therapeutic outcome.

INTRODUCTION
============

Chronic pancreatitis (CP) is characterized by progressive inflammation of the pancreas, which leads to permanent damage of pancreatic structure, function, or both, resulting in episodic or intractable abdominal pain with progressive exocrine and endocrine insufficiency\[[@B1]\]. Inflammation associated with CP occurs in 2.7% to 45.6% of cases and leads to stricture formation in the common bile duct (CBD)\[[@B2]\]. The stasis of bile caused by strictures increases intraluminal pressure in the CBD and induces cholangitis, choledocholithiasis, and secondary biliary cirrhosis\[[@B2],[@B3]\]. Therefore, to reduce CBD pressure, biliary dilation for benign biliary stricture (BBS) should be attempted, while pressure increase as a result of CP can be managed by surgery or endoscopic therapy.

Nealon et al\[[@B4]\] reported that surgical intervention offered a definitive solution for BBS, but was associated with significant morbidity and mortality. Endoscopic biliary dilation by endoscopic retrograde cholangiopancreatography (ERCP) is less invasive than surgery and is the most successful option for patients who are not candidates for surgery\[[@B5]-[@B7]\]. Thus, the European Society of Gastrointestinal Endoscopy (ESGE) has recommended endoscopic therapy as a useful therapeutic approach for BBS\[[@B8]\].

A previous study reported the effectiveness of endoscopic therapy with a single stent for BBS due to CP\[[@B9]\]. By comparing single *vs* multiple simultaneous biliary stenting for treatment of strictures, use of multiple stents appeared to be superior to use of a single stent\[[@B10]\]. Other studies suggest that sequential endoscopic insertion of multiple biliary stents leads to medium and long-term success of stricture dilation\[[@B11],[@B12]\]. Patients with calcifications of the pancreatic head were identified as a group nonresponsive to endoscopic single stent insertion\[[@B9]\] and BBS with pancreatic stones was reported as intractable to therapy with multiple biliary stenting\[[@B12]\]. However, the efficacy of multiple biliary stenting for patients with pancreatic stones has not been investigated in detail and predictive factors of therapeutic success remain undefined. The aim of this study was to assess the usefulness of endoscopic therapy for refractory BBS as a result of chronic calcifying pancreatitis with multiple biliary stenting, and to clarify predictors.

MATERIALS AND METHODS
=====================

Patients
--------

From November 2012 to April 2014, 50 patients with CP visited at the Chiba University Hospital. Of these 50 patients, ten consecutive patients for whom endoscopic therapy with a single stent was unsuccessful were evaluated. Patients aged \< 20 years and with a diagnosis of malignant diseases, existence of coagulopathy, a history of biliary surgery, inability to provide informed consent, or medical contraindications for multiple biliary stenting were excluded from the study. Patients were followed after therapy and interviewed for symptoms of cholestasis. Biochemical testing of liver function was performed at each visit. Written informed consent was obtained from all patients who underwent endoscopic therapy. The study protocol was approved by the institutional review board of Chiba University.

Procedure
---------

Side-viewing duodenoscopes (JF-240/260V, TJF-260V; Olympus Medical Systems, Tokyo, Japan) were used to perform all endoscopic procedures. Endoscopic sphincterotomy was performed for all patients. After insertion of a catheter into the CBD, the existence of a BBS was evaluated and the length of the stricture and CBD diameter, which was upstream of the stricture, was measured by cholangiography in all patients. A flexible guide wire was passed through the stricture and a single plastic stent was inserted beyond the stricture. Plastic stents (7F, 8.5F, and 10F) and increased stents at intervals of 2 or 3 mo were used to avoid clogging and development of cholangitis\[[@B13]\]. When symptoms and abnormal liver function test results following cholestasis appeared, stents or exchanged stents were inserted. All stents were removed approximately one year after initial stenting. Then, the stricture and CBD diameter were evaluated by comparisons with values before therapy.

Outcomes and definitions
------------------------

The main study outcome was the usefulness of multiple biliary stenting for refractory BBSs for symptom relief and maintenance. Diagnosis of CP was based on clinical history and morphological abnormalities of the pancreas, as identified by computed tomography, magnetic resonance cholangiopancreatography, ERCP, and endoscopic ultrasound\[[@B14]\]. Diagnosis of a BBS was based on signs and symptoms of biliary obstruction and evidence of upstream biliary dilatation on imaging\[[@B15]\]. Symptomatic biliary obstruction was defined by clinical and laboratory findings of obstructive jaundice. The stricture was considered sufficiently dilated if there was easy passage of an 8.5 mm balloon and rapid emptying of contrast was evident fluoroscopically\[[@B12]\]. Accordingly, patients with complete stricture dilation were included in the complete group and those with incomplete stricture dilation were included in the incomplete group. Characteristics of the two groups were compared to identify therapeutic predictors. Patient sex, age, body mass index (BMI), etiology, history of alcohol abuse, duration of CP, treatment period, CBD diameter, length of stricture, number of pancreatic stones, pancreatic stone location, pancreatic stone diameter, number of ERCP sessions, and number of biliary stents were evaluated as potential predictors. During the follow-up period, symptom relapse was defined as the appearance of symptomatic biliary obstruction. Complications related to endoscopic therapy were recorded. The severity of these complications was defined and graded according to the consensus criteria proposed by Cotton et al\[[@B16]\].

Statistical analysis
--------------------

The Mann-Whitney *U* test was used to compare continuous variables, while the Fisher's exact test was used for comparison of categorical variables. The Wilcoxon signed-rank test was used to identify differences in the median values of proposed predictors. A probability (*P*) value of \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS software version 20.0 (IBM-SPSS, Inc., Chicago, IL, United States).

RESULTS
=======

Patients
--------

Baseline patient characteristics, imaging findings, and interventions of all patients enrolled in this study are summarized in Table [1](#T1){ref-type="table"}. ERCP procedures were tolerated in all patients. The mean number of biliary stents was 4.1 ± 1.2. Completion of endoscopic therapy was achieved in eight (80.0%) patients. Complete stricture dilation after therapy was achieved in six (60.0%) patients. BBS was not improved in two (20%) patients, thus biliary stents were inserted. CBD diameter was significantly improved after therapy (before therapy; 12.5 ± 2.7 mm, after therapy; 8.7 ± 3.9 mm, *P* = 0.022).

###### 

Baseline patient characteristics, imaging findings, and interventions before treatment (*n* = 10)

  **Variable**                                       **Value**
  -------------------------------------------------- --------------
  Patient characteristics                            
  Sex, *n* (%)                                       
  Male                                               10 (100.0)
  Female                                             0 (0.0)
  Age, mean ± SD, yr                                 56.9 ± 6.9
  BMI, mean ± SD, kg/m^2^                            19.2 ± 2.6
  Etiology, *n* (%)                                  
  Alcohol                                            9 (90.0)
  Other                                              1 (10.0)
  Alcohol abuse, *n* (%)                             
  Presence                                           8 (80.0)
  Absence                                            2 (20.0)
  Duration of CP, mean ± SD, mo                      106.4 ± 72.4
  Treatment period, mean ± SD, d                     350.6 ± 61.0
  Follow up period, mean ± SD, mo (complete group)   20.6 ± 7.3
  Imaging findings                                   
  CBD diameter, mean ± SD, mm                        12.5 ± 2.7
  Length of stricture, mean ± SD, mm                 23.9 ± 5.7
  No. of pancreatic stones, *n* (%)                  
  Single                                             5 (50.0)
  Multiple                                           5 (50.0)
  Pancreatic stone location, *n* (%)                 
  Head                                               10 (100.0)
  Body + Tail                                        0 (0.0)
  Pancreatic stone diameter, mean ± SD, mm           10.2 ± 5.5
  Interventions                                      
  No. of ERCP sessions, mean ± SD                    4.5 ± 1.0
  No. of stents, mean ± SD                           4.1 ± 1.2
  Dilation of CBD stricture, *n* (%)                 
  Presence                                           0 (0.0)
  Absence                                            10 (100.0)

BMI: Body mass index; CBD: Common bile duct; CP: Chronic pancreatitis; ERCP: Endoscopic retrograde cholangiopancreatography.

Outcomes
--------

All patients were male and had pancreatic stones in the pancreatic head. Therefore, patient sex and pancreatic stone location were excluded from analysis of therapeutic outcome predictors. Patients' age, BMI, etiology history of alcohol abuse, duration of CP, treatment period, number of pancreatic stones, pancreatic stone diameter, number of ERCP sessions, and number of biliary stents were similar in complete and incomplete groups. CBD diameter improvement was more significant in the complete group than the incomplete group (6.1 ± 1.8 mm *vs* 13.7 ± 2.2 mm, respectively, *P* = 0.010). Furthermore, only the stricture length was significantly associated with complete stricture dilation (complete group; 20.5 ± 3.0 mm, incomplete group; 29.0 ± 5.1 mm, *P* = 0.011) (Table [2](#T2){ref-type="table"}). Successful results were obtained only in patients with a stricture length of less than 24.0 mm (Table [3](#T3){ref-type="table"}, Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

![Endoscopic retrograde cholangiopancreatography pictures of successful endoscopic stenting in a male patient with a short stricture (19.3 mm). A: Before stent therapy; B: After 1 year of stent therapy.](WJGE-9-12-g001){#F1}

###### 

Univariate analysis of factors predicting complete stricture improvement

  **Variable**                                 **Complete (*n* = 6)**   **Incomplete (*n* = 4)**   ***P* value**
  -------------------------------------------- ------------------------ -------------------------- ---------------
  Patient characteristics                                                                          
  Sex, *n* (%)                                                                                     
  Male                                         6 (100.0)                4 (100.0)                  
  Female                                       0 (0.0)                  0 (0.0)                    
  Age, mean ± SD, yr                           58.8 ± 8.2               54.0 ± 3.4                 0.61
  BMI, mean ± SD, kg/m^2^                      18.0 ± 1.7               20.6 ± 3.1                 0.114
  Etiology, *n* (%)                                                                                0.6
  Alcohol                                      5 (83.3)                 4 (100.0)                  
  Other                                        1 (16.7)                 0 (0.0)                    
  Alcohol abuse, *n* (%)                                                                           0.667
  Presence                                     1 (16.7)                 1 (25.0)                   
  Absence                                      5 (83.3)                 3 (75.0)                   
  Duration of CP, mean ± SD, mo                83.7 ± 79.4              140.5 ± 51.4               0.257
  Treatment period, mean ± SD, d               384.5 ± 16.4             299.8 ± 70.6               0.171
  Imaging findings                                                                                 
  CBD diameter before therapy, mean ± SD, mm   12.4 ± 2.3               12.8 ± 3.7                 0.762
  Length of stricture, mean ± SD, mm           20.5 ± 3.0               29.0 ± 5.1                 0.011
  No. of pancreatic stones, *n* (%)                                                                0.738
  Single                                       3 (50.0)                 2 (50.0)                   
  Multiple                                     3 (50.0)                 2 (50.0)                   
  Pancreatic stone location, *n* (%)                                                               
  Head                                         6 (100.0)                4 (100.0)                  
  Body + Tail                                  0 (0.0)                  0 (0.0)                    
  Pancreatic stone diameter, mean ± SD, mm     7.4 ± 3.7                14.2 ± 6.2                 0.067
  Interventions                                                                                    
  No. of ERCP sessions, mean ± SD              4.5 ± 0.8                4.5 ± 1.3                  \> 0.999
  No. of biliary stents, mean ± SD             4.0 ± 0.9                4.3 ± 1.7                  0.767

BMI: Body mass index; CBD: Common bile duct; CP: Chronic pancreatitis; ERCP: Endoscopic retrograde cholangiopancreatography.

![Failure of endoscopic stenting of common bile duct stricture demonstrated by endoscopic retrograde cholangiopancreatography findings in a male patient with a long stricture (36.0 mm). A: Before stent therapy; B: After 1 year of stent therapy.](WJGE-9-12-g002){#F2}

###### 

Outcomes of multiple biliary stenting in association with stricture length

  **Patient No**.   **Length of stricture (mm)**   **Outcomes of stricture dilation**
  ----------------- ------------------------------ ------------------------------------
  1                 23.2                           Complete
  2                 20.7                           Complete
  3                 19.3                           Complete
  4                 36                             Incomplete
  5                 20.4                           Complete
  6                 24.9                           Incomplete
  7                 29.4                           Incomplete
  8                 25.5                           Incomplete
  9                 24                             Complete
  10                15.5                           Complete

All six patients who achieved complete stricture dilation at least 6 mo after therapy were followed-up for a mean period of 20.6 ± 7.3 mo. During the follow-up period, there was no incidence of recurrence of symptomatic biliary obstruction.

Complications
-------------

Endoscopic therapy could not be completed in two (20%) patients because of acute cholangitis and abdominal abscess, respectively. Therefore, each underwent endoscopic biliary stenting and both recovered following conservative therapy. There were no complications related to ERCP. No instance of severe complication or patient death was noted during the follow-up period.

DISCUSSION
==========

BBS formation is a common complication from either hepato-biliary surgery or diseases, such as CP and primary sclerosing cholangitis, among others\[[@B17]\]. BBS complicates the course of CP in 3% to 23% of patients\[[@B18]\]. BBS causes cholestasis that frequently results in cholangitis. Therefore, endoscopic therapy or surgery for BBS should be attempted. A postoperative BBS is managed with endoscopic therapy, which can improve long-term and very long-term results\[[@B12],[@B19],[@B20]\]. According to the ESGE guidelines, if endoscopic therapy is selected for BBS caused by CP, temporary (one-year) placement of multiple, side-by-side, plastic biliary stents is recommended\[[@B8]\]. Therefore, many patients with BBS caused by CP are managed with multiple biliary stenting. However, Draganov et al\[[@B12]\] reported that endoscopic therapy for these patients tended to be more unsuccessful than for patients with postoperative stricture and the results are worse for those with pancreatic stones. This study aimed to evaluate the efficacy of endoscopic therapy for refractory BBS caused by chronic calcifying pancreatitis with multiple biliary stenting and to clarify predictors of therapeutic success.

Alcohol is the most common cause of CP in Japan\[[@B21]\] and is regarded as the leading cause of CP in Western countries\[[@B14]\]. Disease in patients with alcoholic CP often progresses to pancreatic degeneration and pancreatic stone formation occurs more rapidly than in those with idiopathic CP\[[@B22]\]. Moreover, patient compliance tends to be poor\[[@B8]\]. Our study had a relatively larger proportion of patients with alcoholic CP (90.0%) than reported in previous studies (54.1%-69.0%)\[[@B6],[@B9]\]. Since all patients in our study had refractory BBS, those with alcoholic CP were likely the majority. Although alcoholic CP mainly affects men\[[@B14]\], prognosis of all patients in this study might be generally consistent with that of males.

Biliary stenting was routinely exchanged every 3 mo to avoid clogging and resulting cholangitis based on a study by Dumonceau et al\[[@B8]\] and supported by findings of Greiner's group\[[@B13],[@B23]\]. Besides, the ESGE recommends temporary (one-year) placement of multiple, side-by-side, plastic biliary stents. In our study, the mean number of biliary stents was 4.1 ± 1.2 and the mean number of ERCP sessions was 4.5 ± 1.0, similar to those reported in previous studies\[[@B5],[@B6],[@B10]-[@B12],[@B19],[@B24]\].

Patients with BBS caused by CP were previously treated by single stent insertion to dilate the stricture, according to the recommendations of Kahl et al\[[@B9]\]. Endoscopic therapy was successful for some patients, especially those with a short BBS length. Although the presence of calcification in the pancreatic head and stricture location according to the Bismuth classification was used to predict complete stricture dilation in previous studies\[[@B9],[@B12]\], no report has investigated the relevance of BBS length. Therefore, we evaluated the impact of BBS length on treatment outcome and found that BBS length was indeed a prognostic factor for procedural success. Calculation of BBS length improves the patient selection procedure for therapy. Although it is important to select patients who are likely to achieve favorable outcomes with complete stricture dilation, alternative therapies, including surgery, and avoidance of repetitive therapies could improve the quality of life of others.

In this study, complete stricture dilation was observed in 60% of patients, consistent with previous studies (44%-92%)\[[@B6],[@B10]-[@B12]\]. The results suggest that multiple biliary stenting is a useful procedure for treatment of refractory BBS.

Complications were observed in two (20.0%) patients: one developed cholangitis and the other an abdominal abscess. Both recovered by conservative therapy and biliary stent insertion. Moreover, the frequency of these findings was comparable with other reports\[[@B6],[@B9],[@B10],[@B12]\].

In our study, the sample size was small and the patients were all male. In addition, this study was investigated by a single center. Additional multicenter studies with large number of patients involving both male and female patient population are needed to confirm our study.

In conclusion, the results of the present study indicated that endoscopic therapy with multiple biliary stenting was effective against refractory BBS caused by chronic calcifying pancreatitis. Moreover, the stricture length was correlated with therapeutic outcomes. A stricture length of \< 24.0 mm is a predictor of good prognosis of complete stricture dilation. Therefore, the use of this threshold could help in the planning of alternative therapeutic options for patients for whom incomplete stricture dilation is likely.
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